Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Affimed’s AFM13 Data Show Potential Of NK Cell Approach

Executive Summary

Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.

You may also be interested in...



Finance Watch: Blackstone Closes $1.6bn Fund To Back Commercial-Stage Companies

Public Company Edition: Blackstone Life Sciences Yield will finance approved products, while the firm’s prior fund supports late-stage programs. Also, Coeptis will merge with a SPAC, Bausch + Lomb secured post-IPO debt, and BioXcel revealed a $260m financing and new subsidiary.

Affimed And BioNTech Immunotherapies Among Ones To Watch At AACR

Affimed looks to build on the splash at last year’s American Association for Cancer Research meeting next month, while BioNTech aims to prove its immunotherapy capabilities with a CAR-T candidate.

ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies

An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel